Emcure Pharmaceuticals Limited EMCURE
NSE · India · Health Technology
INR 1,934.00-9.00 (-0.46%)
Market open· · INR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · INR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Gilead Sciences (NASDAQ:GILD) has expanded six existing royalty-free voluntary licensing agreements to include an investigational once-yearly formulation of lenacapavir for HIV prevention, the company announced. The expanded agreements cover 120 countries with high HIV incidence, primarily low- and lower-middle-income nations.
Strong international performance drives a 35.4% jump in profit after tax, despite a slight dip in gross margins.
Emcure Pharmaceuticals Ltd (BOM:544210) reports a 13% revenue increase and strategic moves in the obesity market, despite challenges in debt and margin stability.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.